CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 13 enrolled
Drug / intervention
Aripiprazoledrug
Likely dose
Aripiprazole 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01028820
NCT01028820Phase 4Completed
CompareCT.gov

Pilot Study of the Effect of Aripiprazole Treatment in Autism Spectrum Disorders on Functional Magnetic Resonance Imaging (fMRI) Activation Patterns and Symptoms

University of North Carolina, Chapel Hill·interventional·Posted Dec 9, 2009·Updated Mar 11, 2014

In Brief

A Phase 4 clinical trial evaluating Aripiprazole for Autism Spectrum Disorder. Completed, enrolled 13 participants across 2 sites.

Detailed Summary

This is an 8 week research study of aripiprazole (abilify) which is used to reduce irritable behaviors in autism spectrum disorders. All participants will receive active study medication. Participants will also receive diagnostic and cognitive evaluations at no cost. Participants will be required to undergo two fMRI (functional magnetic resonance imaging scans) where we will take pictures of your brain while performing simple tasks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAutism Spectrum Disorder
CountriesUnited States
CollaboratorsDuke University, National Institute of Mental Health (NIMH)

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 9, 2009
Enrollment StartAug 1, 2009
Primary CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 16.6 years ago

Interventions

Aripiprazoledrug

8 weeks, starting dosage 5mg titrating up 5mg every week as needed to maximum dosage of 25mg daily